Clinical Transplantation · 2014 · 13 citations · 18 references
Life SciencesImmunologyAutoimmunityClinical ImmunologyTransplant ImmunologyAntibody-mediated RejectionAutoantibodiesAutoimmune DiseasesTransplant RejectionAutoantibody AssaysAutoantibody PathogenesisAutoimmune Liver Disease AssessmentBiomarkers Of Graft DysfunctionGraft Dysfunction Evaluation
Autoantibodies are frequently detected after liver transplantation, yet their clinical significance remains unclear. The study sought to determine autoantibody prevalence before and up to five years after transplantation, identify potential predictors, and examine their relationship with graft dysfunction. Researchers retrospectively analyzed 92 consecutive liver transplant recipients with prospectively stored sera, measuring autoantibodies by immunofluorescence. Autoantibody prevalence rose markedly post‑transplant (64 % vs 27 % at ≥1:80, 35.9 % vs 8.7 % at ≥1:160), was unrelated to donor/recipient factors or immunosuppression, was higher in patients with graft dysfunction at high titers, and no de novo autoimmune hepatitis occurred, indicating that autoantibodies are common but likely nonspecific markers of liver injury.
Autoantibodies are frequently detected after liver transplantation (LT), but their role is unclear. This study was designed to address three points: autoantibody prevalence pre-LT and over time up to five yr after LT, identification of possible predictors of autoantibody formation, and correlation between autoantibodies and graft dysfunction. To these aims, we retrospectively evaluated 92 consecutive LT recipients for whom prospectively stored frozen sera were available for autoantibodies assessment by immunofluorescence. The overall autoantibody prevalence resulted significantly higher after LT than before LT (64% vs. 27%, p < 0.001 and 35.9% vs. 8.7%, p < 0.001 considering cutoff titer of ≥ 1:80 and ≥ 1:160, respectively). Recipient gender, donor age and gender, and indication for LT and main immunosuppressant (cyclosporine vs. tacrolimus) were not associated with the presence of autoantibodies. Patients with graft dysfunction had a significantly higher autoantibody prevalence irrespective of the etiology of liver injury as compared to those patients with persistently normal liver biochemistry, but only for cutoff titers ≥ 1:160 (p = 0.004). No cases of de novo autoimmune hepatitis were observed. In conclusion, autoantibodies are very frequently detected after LT also at high titers and their association with graft dysfunction likely represents an aspecific indicator of liver injury.
18
Diagnosis and Management of Autoimmune Hepatitis
Michael P. Manns, Albert J. Czaja, James D. Gorham et al. · Hepatology · 2010 · 1.4K citations · Full text
Diagnosis and treatment of autoimmune hepatitis
Albert J. Czaja, Deborah K. Freese · Hepatology · 2002 · 563 citations · Full text
De-novo autoimmune hepatitis after liver transplantation
Nanda Kerkar, Nedim Hadzic, Edward T. Davies et al. · The Lancet · 1998 · 415 citations
Progressive histological damage in liver allografts following pediatric liver transplantation
Helen Evans, Déirdre Kelly, Patrick McKiernan et al. · Hepatology · 2006 · 302 citations · Full text
Medicine, Pathology, Pediatrics +15